We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00098514
Recruitment Status : Completed
First Posted : December 8, 2004
Last Update Posted : December 18, 2017
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Geoffrey Shapiro, MD, PhD, Dana-Farber Cancer Institute

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase I trial is studying side effects, best way to give, and best dose of talotrexin in treating patients with advanced or recurrent solid tumors.


Condition or disease Intervention/treatment Phase
Unspecified Adult Solid Tumor, Protocol Specific Drug: talotrexin ammonium Phase 1

Detailed Description:

OBJECTIVES:

Primary

  • Determine the maximum tolerated dose of talotrexin in patients in patients with advanced or recurrent solid tumors.
  • Determine the safety of this drug in these patients.
  • Determine the dose-limiting toxic effects of this drug in these patients.

Secondary

  • Determine the pharmacokinetics of this drug in these patients.
  • Correlate pharmacokinetic parameters of this drug or patient characteristics with drug-related toxicity in these patients.
  • Determine, preliminarily, the antitumor efficacy of this drug in these patients.

OUTLINE: This is an open-label, dose-escalation, multicenter study.

Patients receive talotrexin IV over 5 minutes on day 1 OR days 1 and 8 OR days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 1-6 patients receive escalating doses of talotrexin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6-10 patients are treated at the MTD.

Patients are followed at 1 month.

PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 9-12 months.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Intervention Model: Single Group Assignment
Intervention Model Description: There were 7 potential PT523 single agent dose levels to be evaluated in this phase I study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study Of PT523 In Patients With Solid Tumors
Actual Study Start Date : December 2003
Primary Completion Date : March 2007
Study Completion Date : May 2011

Arm Intervention/treatment
Experimental: Dose Level 1a
10 mg/m2 dose of PT523 administered day 1 of a 28-day cycle as a 5 minute IV infusion (IV bolus)
Drug: talotrexin ammonium
Experimental: Dose Level 1b
5 mg/m2 dose of PT523 administered days 1 and 8 of a 28-day cycle as a 5 minute IV infusion
Drug: talotrexin ammonium
Experimental: Dose Level 1c
3.33 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
Drug: talotrexin ammonium
Experimental: Dose Level 2
5 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
Drug: talotrexin ammonium
Experimental: Dose Level 3
7.5 mg/m2 dose (or 6.7 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
Drug: talotrexin ammonium
Experimental: Dose Level 4
11.25 mg/m2 dose (or 9 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
Drug: talotrexin ammonium
Experimental: Dose Level 5
17 mg/m2 dose (or 12 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
Drug: talotrexin ammonium




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of malignant solid tumor

    • Metastatic or inoperable disease
  • No known curative or survival-prolonging palliative therapy exists OR failed these prior therapies
  • No leukemia
  • No primary CNS tumor
  • No third-space fluid collection (i.e., pleural effusion, ascites)

    • Clinically insignificant small pleural or peritoneal effusions identified by CT scan, MRI, or other diagnostic test allowed
  • No active* brain metastases, including the following:

    • Evidence of cerebral edema by CT scan or MRI
    • Progression since prior imaging study
    • Requirement for steroids
    • Clinical symptoms of/from brain metastases NOTE: *Treated and/or stable brain metastasis allowed provided patient is asymptomatic

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • At least 2 months

Hematopoietic

  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • RBC folate ≥ lower limit of normal

Hepatic

  • Bilirubin normal
  • SGOT and SGPT ≤ 2.5 times upper limit of normal

Renal

  • Creatinine clearance ≥ 50 mL/min

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other uncontrolled serious medical or psychiatric illness

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • No prior bone marrow transplantation

Chemotherapy

  • More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

Endocrine therapy

  • See Disease Characteristics

Radiotherapy

  • More than 3 weeks since prior radiotherapy
  • No concurrent radiotherapy

Surgery

  • At least 3 weeks since prior surgery

Other

  • Recovered from prior therapy
  • More than 3 weeks since prior antifolate therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00098514


Locations
United States, Massachusetts
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Investigators
Principal Investigator: Joseph Paul Eder, MD

Responsible Party: Geoffrey Shapiro, MD, PhD, Director, Early Drug Development Center, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT00098514     History of Changes
Other Study ID Numbers: 03-183
P30CA006516 ( U.S. NIH Grant/Contract )
CDR0000400150
NCI-6400
DFCI-IRB-03183
HANABIO-DFCI-02000
First Posted: December 8, 2004    Key Record Dates
Last Update Posted: December 18, 2017
Last Verified: December 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Geoffrey Shapiro, MD, PhD, Dana-Farber Cancer Institute:
unspecified adult solid tumor, protocol specific